Synairgen (LON:SNG) Stock Price Down 2.4% – Should You Sell?

Shares of Synairgen plc (LON:SNG) fell 2.4% during trading on Tuesday . The company traded as low as GBX 2.05 ($0.03) and last traded at GBX 2.19 ($0.03). 1,204,007 shares traded hands during mid-day trading, a decline of 10% from the average session volume of 1,343,892 shares. The stock had previously closed at GBX 2.25 ($0.03).

Synairgen Trading Down 13.1 %

The business has a 50 day moving average price of GBX 3.73 and a 200 day moving average price of GBX 4. The company has a market capitalization of £3.93 million, a P/E ratio of -65.00 and a beta of -2.23. The company has a current ratio of 6.77, a quick ratio of 6.35 and a debt-to-equity ratio of 0.09.

Synairgen Company Profile

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease.

Synairgen is conducting a double blind, placebo-controlled clinical trial in COVID-19 patients (SG016).